ALNY vs WVE
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. WVE: Wave Life Sciences is a clinical-stage biotech company developing stereopure nucleic acid therapeutics via its proprietary PRISM platform to treat genetically defined diseases.
Side-by-side fundamentals
| Metric | ALNY | WVE | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $230.71 | $3.42 | |
| Market cap | $30.9B | $674M | |
| P/E as of 2026-10-20 | 40.19 | n/a | |
| Net margin FY2025, SEC XBRL | +8.4% | -478.3% | ALNY higher |
| Operating margin FY2025, SEC XBRL | +13.5% | -504.1% | ALNY higher |
| ROE FY2025, SEC XBRL | +39.8% | -39.4% | ALNY higher |
| ROA FY2025, SEC XBRL | +6.3% | -32.0% | ALNY higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +65.2% | -60.5% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +127.1% | WVE higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.81 | 1.46 | |
| 1-year return as of 2026-10-20 close | -53.0% | -56.2% | ALNY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.